Evidence review board
Research-use only. Expert review and retrospective validation are required.
Reviewer states
Decisions that gate report export
- Pending reviewAwaiting expert review.
- Needs evidenceReviewer flagged the evidence trail as incomplete.
- Accepted for reportApproved for inclusion in the research brief.
- RejectedExcluded from the brief, with reason.
- Limitation unresolvedEvidence gap noted for retrospective validation.
Research workflow
Inspect signals before reporting
This page is where the researcher checks why each signal or hypothesis is surfaced before turning it into a report.
Accepted for report
0
Ready to include in the research brief
Needs evidence
0
Reviewer requested a stronger evidence trail
Pending review
5
Awaiting expert interpretation and notes
Limitation unresolved
0
Carry to retrospective validation or exclude from export
Mutation review queue
Ranked signals with linked hypothesis classes
Open a row to review the evidence trail in the side panel.
| Rank | Signal | Pathway | Tier | Score | Hypothesis | Status | Action |
|---|---|---|---|---|---|---|---|
| 1 | EGFR L858R Open for interpretation, limitation, and next validation review. | EGFR/ERBB signalling | Strong | 94 | EGFR inhibitor class | Pending review | |
| 2 | TP53 R175H Open for interpretation, limitation, and next validation review. | p53 tumour suppressor pathway | Strong | 88 | p53 pathway reactivation research compounds | Pending review | |
| 3 | KRAS G12C Open for interpretation, limitation, and next validation review. | RAS/MAPK signalling | Moderate | 82 | MEK pathway inhibitor class | Pending review | |
| 4 | ALK Rearrangement signal Open for interpretation, limitation, and next validation review. | ALK tyrosine kinase signalling | Emerging | 74 | ALK inhibitor class | Pending review | |
| 5 | MET Exon 14 skipping Open for interpretation, limitation, and next validation review. | RTK/MAPK signalling | Moderate | 72 | MET pathway inhibitor class | Pending review |